← Signal Board

YD Bio Ltd financial statements

NASDAQ:YDES · Nasdaq
$5.79-1.53%
2026-10-08 close · prelim

YD Bio Ltd's published financial data is dated 2026-10-04. 2024 revenue was $1M. 2024 operating profit was −$1M.

Reported results

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 25.99
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
25.99
Beneish M-Score
-0.23

Statistical manipulation-risk signal

Sloan accrual
6.20%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

3/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score3/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -360%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-2.8% → -286.5%, -283.6%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-286.5%
Interest coverage
-1,898.6x
Return on equity (ROE)
-21.4%

Operating margin −5pp

Operating loss
Interest coverageBase -1,898.6x adverse case -1,931.8x
Return on equity (ROE)Base -21.4% adverse case -22.6%

Revenue −15%

Interest coverage risk
Interest coverageBase -1,898.6x adverse case -1,613.8x
Return on equity (ROE)Base -21.4% adverse case -18.9%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -1,898.6x adverse case -233.9x
Return on equity (ROE)Base -21.4% adverse case -22.3%

Interest coverage limit

Already below the limit by 286.6pp

Interest coverage limit at an operating margin of 0.2%

Interest expense coverage threshold

YD Bio Ltd notifications

Quantus Signal · live data · not investment advice · Privacy Policy